N,N-dimethyltryptamine--a possible relationship to schizophrenia?
Wyatt, R.J.; Gillin, J.C.; Kaplan, J.; Stillman, R.; Mandel, L.; Ahn, H.S.; VandenHeuvel, W.J.; Walker, R.W.
Advances in Biochemical Psychopharmacology 11: 299-313
1974
ISSN/ISBN: 0065-2229 PMID: 4602668 Document Number: 78973
Document emailed within 1 workday
Related Documents
Gillin, J.C.; Wyatt, R.J. 1976: Evidence for and against the involvement of N,N-dimethyl-tryptamine (DMT) and 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) in schizophrenia Psychopharmacology Bulletin 12(4): 12-13Goswami, S.; Singh, G.; Mattoo, S.K.; Basu, D. 2003: Courses of substance use and schizophrenia in the dual-diagnosis patients: is there a relationship? Indian Journal of Medical Sciences 57(8): 338-346
Chen, X-shi.; Lu, Y-zhi.; Wang, J-jun.; Wang, H-xing.; Zhang, M-dao.; Lou, F-yin.; Chen, C. 2007: Relationship between event-related potential P300 and first episode schizophrenia Chinese Medical Journal 120(4): 339-341
İnanç, L.; Sevinç, E.ün.; Semiz, Üm.B.şa. 2019: Relationship between Alexithymia, Depression and the Negative Symptoms in Schizophrenia with and without Deficit Syndrome Turk Psikiyatri Dergisi 30(4): 225-235
Yao, J.; Wang, B.-J. 2014: Relationship between genetic polymorphism of dopamine receptor and schizophrenia and its forensic significance Fa Yi Xue Za Zhi 30(3): 202-206
Lee, S. 2001: Atypical antipsychotics in the treatment of schizophrenia. "Informed relationship between doctor and patient" does not exist in many parts of the world Bmj 322(7291): 925
Krischer, K.; Pfeiffer, C.C. 1973: Biochemical relationship between kryptopyrrole (mauve factor and trans-3-methyl-2-hexenoic acid (schizophrenia odor) Research Communications in Chemical Pathology and Pharmacology 5(1): 9-15
Tomita, K.; Takahashi, N.; Saito, S.; Maeno, N.; Iwamoto, K.; Yoshida, K.; Kimura, H.; Iidaka, T.; Ozaki, N. 2011: Relationship of psychopathological symptoms and cognitive function to subjective quality of life in patients with chronic schizophrenia Seishin Shinkeigaku Zasshi 113(2): 135-143
Bigelow, L.B.; Kirch, D.G.; Braun, T.; Korpi, E.R.; Wagner, R.L.; Zalcman, S.; Wyatt, R.J. 1985: Absence of relationship of serum haloperidol concentration and clinical response in chronic schizophrenia: a fixed-dose study Psychopharmacology Bulletin 21(1): 66-68
Morley, B.J.; Bradley, R.J. 1977: Spectral analysis of mouse EEG after the administration of N,N-dimethyltryptamine Biological Psychiatry 12(6): 757-769
Mandel, L.R. 1974: Dimethyltryptamine: its biosynthesis and possible role in mental disease Psychopharmacology Bulletin 10(3): 55-56
Checkley, S.A.; Oon, M.C.; Rodnight, R.; Murphy, M.P.; Williams, R.S.; Birley, J.L. 1979: Urinary excretion of dimethyltryptamine in liver disease American Journal of Psychiatry 136(4a): 439-441
Lipinski, J.F.; Mandel, L.R.; Ahn, H.S.; Vanden Heuvel, W.J.; Walker, R.W. 1974: Blood dimethyltryptamine concentrations in psychotic disorders Biological Psychiatry 9(1): 89-91
Sangiah, S.; Gomez, M.V.; Domino, E.F. 1979: Accumulation of N,N-dimethyltryptamine in rat brain cortical slices Biological Psychiatry 14(6): 925-936
Gillin, J.C.; Tinklenberg, J.; Stoff, D.M.; Stillman, R.; Shortlidge, J.S.; Wyatt, R.J. 1976: 5-Methoxy-N,N-dimethyltryptamine: behavioral and toxicological effects in animals Biological Psychiatry 11(3): 355-358
Quock, R.M.; Lum, M.H.; Small, S.F. 1979: Interaction of N,N-dimethyltryptamine with central neuroaminergic receptor blocking agents Proceedings of the Western Pharmacology Society 22: 217-218
Wang Lu, L.J.; Demetriou, S.K.; Domino, E.F. 1978: Effects of various neuroleptics, phenobarbital and SKF 525-A on dimethyltryptamine content in rat brain and liver Archives Internationales de Pharmacodynamie et de Therapie 232(1): 117-133
Stoff, D.M.; Moja, E.A.; Gillin, J.C.; Wyatt, R.J. 1977: Dose response and time course effects of N,N-dimethyltryptamine on disruption of rat shuttlebox avoidance Biological Psychiatry 12(3): 339-346
Mandel, L.R.; Rokach, J.; Rooney, C.S.; Cragoe, E.J. 1978: Inhibition of dimethyltryptamine biosynthesis by N,N'-bis-(3-methyl-2-thiazolidinylidene)succinamide (I) and 2-imino-3-methylthiazolidine (II) Molecular Pharmacology 14(5): 930-939
Matsumoto, H.; Pietruszewska, I. 1978: Urinary excretion of bufotenin, N,N-dimethyltryptamine and 3,4-dimethoxyphenylethylamine and the clinical picture of mental disorders Psychiatria Polska 12(2): 189-197